A randomised trial of alpha-interferon versus medroxyprogesterone acetate for metastatic renal carcinoma

Submission date	Recruitment status No longer recruiting	Prospectively registered		
28/02/2001		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
28/02/2001	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
04/09/2009	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mrs Pat Cook

Contact details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA pat.cook@ctu.mrc.ac.uk

Additional identifiers

Protocol serial number REO1

Study information

Scientific Title

Study objectives

To establish whether, in patients with metastatic renal carcinoma, recombinant alpha-interferon has any advantage over medroxyprogesterone acetate.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cancer

Interventions

- 1. One group receives recombinant alpha-interferon
- 2. The other group receives medroxyprogesterone

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

alpha-interferon versus medroxyprogesterone acetate

Primary outcome(s)

- 1. Survival time
- 2. Response rate
- 3. Time to progression
- 4. Quality of life

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/12/1998

Eligibility

Key inclusion criteria

- 1. Histologically or cytologically proven renal cell carcinoma with evaluable metastatic disease
- 2. World Health Organisation (WHO) performance status 0-2
- 3. No previous malignancy (except non-melanotic skin cancer or in situ carcinoma of the cervix)
- 4. Three groups of patients are eligible:
- (a) Those patients who have had a nephrectomy in the past and develop metastatic disease during follow up. Patients can be randomised when metastatic disease has been confirmed and the patient fits the other eligibility criteria.
- (b) Those patients who present with metastatic disease and have had the primary tumour removed within the last 4 weeks. Patients should be randomised once the nephrectomy has been performed and the wound has healed.
- (c) Those patients who present with metastatic disease where nephrectomy is not planned. Patients can be randomised at presentation.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Patients with cardiac disease which may preclude alpha-interferon or those with known brain metastases must be excluded. No previous RT, hormonal, cytotoxic or immuno-therapy within 12 weeks of the proposed date of randomisation.

Date of first enrolment

01/01/1992

Date of final enrolment

01/12/1998

Locations

Countries of recruitment

United Kingdom

England

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	early results	02/01/1999		Yes	No
Results article	results	23/02/2004		Yes	No
Other publications	design described	15/11/1994		Yes	No